Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
<strong>Background</strong> Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and...
Prif Awduron: | Thriemer, K, Degaga, TS, Christian, M, Alam, MS, Ley, B, Hossain, MS, Kibria, MG, Tego, TT, Abate, DT, Weston, S, Karahalios, A, Rajasekhar, M, Simpson, JA, Rumaseb, A, Mnjala, H, Lee, G, Anose, RT, Kidane, FG, Woyessa, A, Baird, K, Sutanto, I, Hailu, A, Price, RN |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
BioMed Central
2022
|
Eitemau Tebyg
-
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial
gan: Thriemer, K, et al.
Cyhoeddwyd: (2022) -
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
gan: Kamala Thriemer, et al.
Cyhoeddwyd: (2022-05-01) -
Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned
gan: Degaga, TS, et al.
Cyhoeddwyd: (2020) -
Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned
gan: Tamiru S. Degaga, et al.
Cyhoeddwyd: (2020-06-01) -
Adapting international clinical trials during COVID-19 and beyond
gan: Thriemer, K, et al.
Cyhoeddwyd: (2023)